Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificity.

Biochimica Et Biophysica Acta. Proteins and Proteomics
N SevillanoC S Craik

Abstract

Affinity maturation of U33, a recombinant Fab inhibitor of uPA, was used to improve the affinity and the inhibitory effect compared to the parental Fab. Arginine scanning of the six CDR loops of U33 was done to identify initial binding determinants since uPA prefers arginine in its primary substrate binding pocket. Two CDR loops were selected to create an engineered affinity maturation library of U33 that was diversified around ArgL91 (CDR L3) and ArgH52 (CDR H2). Biopanning of the randomized U33 library under stringent conditions resulted in eight Fabs with improved binding properties. One of the most potent inhibitors, AB2, exhibited a 13-fold decrease in IC50 when compared to U33 largely due to a decrease in its off rate. To identify contributions of interfacial residues that might undergo structural rearrangement upon interface formation we used X-ray footprinting and mass spectrometry (XFMS). Four residues showed a pronounced decrease in solvent accessibility, and their clustering suggests that AB2 targets the active site and also engages residues in an adjacent pocket unique to human uPA. The 2.9 Å resolution crystal structure of AB2-bound to uPA shows a binding mode in which the CDR L1 loop inserts into the active site c...Continue Reading

References

Aug 5, 1992·Journal of Molecular Biology·R E HawkinsG Winter
Oct 9, 2002·Current Pharmaceutical Design·T W RockwayV L Giranda
Sep 5, 2003·Analytical and Bioanalytical Chemistry·Martin FunovicsChing-Hsuan Tung
Aug 13, 2004·Proceedings of the National Academy of Sciences of the United States of America·Frederic A FellouseSachdev S Sidhu
Mar 25, 2005·Biochemical Society Transactions·X S PuenteC López-Otín
Sep 7, 2006·Nature Reviews. Drug Discovery·Boris Turk
Aug 8, 2007·Journal of Molecular Biology·Evgeny Krissinel, Kim Henrick
Dec 14, 2007·Proceedings of the National Academy of Sciences of the United States of America·Yan WuDaniel Kirchhofer
Dec 21, 2007·The Journal of Pathology·M J DuffyW M Gallagher
Feb 26, 2008·Current Opinion in Genetics & Development·Margot G Paulick, Matthew Bogyo
Jun 3, 2008·Journal of Molecular Biology·Christopher J FaradyCharles S Craik
May 13, 2009·Journal of Chemical Information and Modeling·Thomas A Halgren
Feb 11, 2010·Cancer Research·Molly R DarraghCharles S Craik
Mar 23, 2011·Biochemistry. Biokhimii︠a︡·E P AltshulerA G Katrukha
Oct 1, 2011·Methods : a Companion to Methods in Enzymology·Jungmin KimCharles S Craik
Dec 14, 2011·Journal of Molecular Biology·Eric L SchneiderCharles S Craik
Sep 29, 2012·The Biochemical Journal·Longguang JiangMingdong Huang
Aug 3, 2013·Analytical Biochemistry·Francisco YleraAchim Knappik
Jun 27, 2014·BioMed Research International·V B SulimovV A Sadovnichiy
Feb 13, 2015·Cancer Research·Aaron M LeBeauHenry F VanBrocklin
Sep 20, 2015·Proceedings of the National Academy of Sciences of the United States of America·Sayan GuptaCheryl A Kerfeld
Dec 17, 2015·Expert Opinion on Therapeutic Targets·Shih-Chi SuShun-Fa Yang
Sep 12, 2018·Bioorganic & Medicinal Chemistry Letters·Imadul IslamBrad O Buckman
Oct 8, 2019·Acta Crystallographica. Section D, Structural Biology·Dorothee LiebschnerPaul D Adams

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.